Table 1 Clinical characteristics
|
Controls (n = 15) |
CAD (n = 15) | |
|---|---|---|
| Age (years) | 58.86 ± 2.19 | 61.58 ± 2.60 |
| Sex (M/F) | 11/4 | 10/5 |
| BMI (kg/m2) | 25.69 ± 1.01 | 29.66 ± 1.28* |
| Statin use, n (%) | 3 (20%) | 3 (20%) |
| Anti-hypertensive agents, n (%) | 10 (67%) | 9 (60%) |
| Anti-platelet agents, n (%) | 2 (13%) | 4 (27%) |
| Anti- diabetic agents, n (%) | 4 (27%) | 6 (40%) |
| Organic Nitrates, n (%) | 2 (13%) | 3 (20%) |
| Aspirin, n (%) | 5 (33%) | 6 (40%) |
| DM2, n (%) | 6 (40%) | 8 (53%) |
| Active smokers, n (%) | 3 (20%) | 2 (13%) |
| SBP (mmHg) | 122.93 ± 4.26 | 127.50 ± 5.38 |
| DBP (mmHg) | 73.93 ± 3.79 | 75.33 ± 3.99 |
| Creatinine (mg/dL) | 0.86 ± 0.06 | 0.87 ± 0.07 |
| eGFR (mL/min/1.73 m2) | 60.00 ± 0.01 | 59.80 ± 0.20 |
| TSH (mIU/L) | 2.42 ± 0.52 | 3.33 ± 0.45 |
| T4 (μg/dL) | 8.12 ± 0.86 | 8.12 ± 0.45 |
| T3 (ng/mL) | 1.16 ± 0.04 | 1.14 ± 0.02 |
| Cholesterol (mg/dL) | 147.82 ± 13.28 | 103.08 ± 14.73* |
| Triglycerides (mg/dL) | 99.09 ± 6.49 | 100.40 ± 6.49 |
| Glucose (mg/dL) | 92.84 ± 2.55 | 106.21 ± 6.19* |
| HDL-cholesterol (mg/dL) | 40.67 ± 3.20 | 31.32 ± 2.17* |
| Free HDL-cholesterol (mg/dL) | 10.36 ± 1.71 | 11.77 ± 1.04 |
| Esterified HDL-cholesterol (mg/dL) | 50.91 ± 5.37 | 32.84 ± 4.54* |
| HDL- triglycerides (mg/dL) | 29.63 ± 3.13 | 24.78 ± 1.99 |
| HDL-phospholipids (mg/dL) | 70.31 ± 5.04 | 70.41 ± 5.33 |
| LDL-cholesterol (mg/dL) | 98.18 ± 6.65 | 62.51 ± 4.70* |
| HDL 2b (%) | 17.59 ± 0.82 | 20.83 ± 1.90 |
| HDL 2a (%) | 11.40 ± 0.30 | 12.25 ± 0.46 |
| HDL 3a (%) | 26.82 ± 1.03 | 27.05 ± 0.40 |
| HDL 3b (%) | 18.69 ± 0.40 | 20.29 ± 0.61* |
| HDL 3c (%) | 24.49 ± 1.31 | 20.22 ± 1.44* |
| SYNTAX score | 0.00 (0.00–0.00) | 10.00 (2.00–44.00) |